Log in

VolitionRX Stock Forecast, Price & News

-0.10 (-3.12 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $3.11
50-Day Range N/A
52-Week Range
Now: $3.11
Volume500,018 shs
Average Volume325,322 shs
Market Capitalization$149.03 million
P/E RatioN/A
Dividend YieldN/A
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Read More
VolitionRX logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Medical Laboratories & Research
Previous SymbolNYSEMKT:VNRX
Phone646 650 1351



Sales & Book Value

Annual SalesN/A



Market Cap$149.03 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
-0.10 (-3.12 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of VolitionRX?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for VolitionRX

When is VolitionRX's next earnings date?

VolitionRX is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for VolitionRX

How were VolitionRX's earnings last quarter?

VolitionRX Ltd (NYSEAMERICAN:VNRX) released its earnings results on Thursday, August, 13th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.01. The medical research company had revenue of $0.01 million for the quarter.
View VolitionRX's earnings history

What price target have analysts set for VNRX?

3 analysts have issued 1-year target prices for VolitionRX's shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate VolitionRX's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 146.5% from the stock's current price.
View analysts' price targets for VolitionRX

Who are some of VolitionRX's key competitors?

What other stocks do shareholders of VolitionRX own?

Who are VolitionRX's key executives?

VolitionRX's management team includes the following people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
  • Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
  • Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)
  • Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)

What is VolitionRX's stock symbol?

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

Who are VolitionRX's major shareholders?

VolitionRX's stock is owned by a variety of institutional and retail investors. Top institutional investors include Nuveen Asset Management LLC (0.29%), Bridgeway Capital Management Inc. (0.21%), Bank of New York Mellon Corp (0.19%), Charles Schwab Investment Management Inc. (0.14%), Goldman Sachs Group Inc. (0.14%) and Ovata Capital Management Ltd (0.12%). Company insiders that own VolitionRX stock include Cameron John Reynolds, Corp Ltd Eight, Jason Bradley Md Terrell and Martin Charles Faulkes.
View institutional ownership trends for VolitionRX

Which major investors are selling VolitionRX stock?

VNRX stock was sold by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Advisor Group Holdings Inc., and Bank of America Corp DE. Company insiders that have sold VolitionRX company stock in the last year include Corp Ltd Eight, Jason Bradley Md Terrell, and Martin Charles Faulkes.
View insider buying and selling activity for VolitionRX

Which major investors are buying VolitionRX stock?

VNRX stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Ovata Capital Management Ltd, New York State Common Retirement Fund, Two Sigma Advisers LP, Jane Street Group LLC, and American International Group Inc.. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, Corp Ltd Eight, and Martin Charles Faulkes.
View insider buying and selling activity for VolitionRX

How do I buy shares of VolitionRX?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VolitionRX's stock price today?

One share of VNRX stock can currently be purchased for approximately $3.11.

How big of a company is VolitionRX?

VolitionRX has a market capitalization of $149.03 million. VolitionRX employs 44 workers across the globe.

What is VolitionRX's official website?

The official website for VolitionRX is www.volitionrx.com.

How can I contact VolitionRX?

The medical research company can be reached via phone at 646 650 1351.

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.